AlbuSorb™ Albumin Depletion Kit
- Removes >90% albumin from 30 mg albumin/ml sample
- Affinity-type equivalence, virtually no cross-reactivity with other proteins
- Bind and elute procedure - simply weigh powder, condition the sample, centrifuge and/or filter, and recover the albumin depleted serum
- Economical new surface technology, not based on affinity chromatography
- Mild conditions maintain tertiary structure of proteins and simple transfer to secondary analysis
- The albumin depleted filtrate retains the enzymatic and biological activity
- Removes albumin from samples such as serum, plasma and from species including human, mouse, sheep, bovine, goat, rat, and calf
- The flow through fraction is compatible with LC-MS, activity based protein profiling and proteomic studies.
Albusorb™ is an albumin depletion reagent supplied as a kit with necessary buffers. With 25ul of starting sample, the yield of albumin depleted serum protein is 0.1-0.2 milligrams. Albusorb™ binds albumin from serum or plasma and is compatible with downstream proteomics methods such as protein array pixelation ,1D and 2D gel electrophoresis, LC/MS, and MALDI-TOF MS. Samples are also prepared for biomarker discovery, toxicological studies for new drugs, enzyme assays, protein profiling using SELDI analysis and cytokines research.
AlbuSorb™ binds to albumin, and serum proteins flow through. Removal of albumin allows enhanced detection of low abundance proteins. AlbuSorb™ comes from a silica-based, separation platform utilizing a new combination of surface microenvironments substituted with low molecular substrates that feature drug-binding motifs. Unlike immuno-affinity, the surfaces utilized are disposable eliminating cycle to cycle variance and cross-contamination.
Biotech Support Group has AlbuVoid™™ for albumin depletion plus low abundance serum protein enrichment. Both Albusorb™™ and AlbuVoid™™ are available in AlbuTrial™ kit™. AlbuTrial™ kit™ includes 1 gm of Albusorb™™ and 5 Preps of AlbuVoid™™ with respective buffers.
Click here for the Albusorb™ Product Sheet
Dr.Roy, Matthew Kuruc, et al. "Albumin Removal Reference Applications Report"
Gwenael Pottiez, Pawel Ciborowski. Proteomic Profiling of Cerebrospinal Fluid Expression Profiling In Neuroscience Neuromethods.2012;64:245-270
Happonen KE, Fürst CM, Saxne T et al. PRELP protein inhibits the formation of the complement membrane attack complex.Journal of Biological Chemistry.2012;287(11):8092-100
Holmberg R, Refai E, Höög A.Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences.2011;108(26):10685-9.
Tang MX, Ogawa K, Asamoto M. Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Nutrition and Cancer.2011;63(2):227-33
Holmberg, Rebecka Apolipoprotein CIII and Ljungan virus in diabetes 2010. Doctoral Thesis
Lu Q, Zheng X, McIntosh T Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Analytical Chemistry.2009;81(21):8715-23
Zubiri, Irene, et al. "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis." Journal of proteomics 96 (2014): 92-102.
Berggren, Per Olaf, Yang, Shao-Nian. 2012. Methods For Treating And/Or Limiting Development Of Diabetes.U.S. Patent 20120328630 Kind Code: A1, filed June 25, 2012, and issued December 27, 2012.
|AlbuVoid Binding Buffer AVBB™albuvoid_binding_buffer$0.00|